Don’t let the high cost of brand specialty IBD biologics stand between you and the treatment you need. We help eligible patients access Omvoh Injection (mirikizumab, SC maintenance) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
The Omvoh Injection Prescription Assistance Program is a manufacturer-sponsored initiative that provides Omvoh maintenance therapy at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for IBD patients who are uninsured or underinsured, as well as Medicare Part D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, gastroenterology coordination, prior-authorization documentation, specialty pharmacy logistics, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and annual re-certification — so you focus on your health, not paperwork.
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$4,800.00 | Save ~$4,730/mo |
| CVS Pharmacy | ~$5,000.00 | Save ~$4,930/mo |
| Walmart | ~$4,400.00 | Save ~$4,330/mo |
| Costco | ~$4,200.00 | Save ~$4,130/mo |
| Specialty Pharmacy | ~$4,300.00 | Save ~$4,230/mo |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
1 Medications
2 Medications
3 Medications
4+ Medications
The Patient Assistance Program is free to apply for and provides Omvoh Injection at no medication cost if approved. But the process involves detailed applications, gastroenterology coordination, prior-authorization documentation, specialty pharmacy logistics, and ongoing renewal management. Our $69.95/month service covers full advocacy: applications, doctor coordination, documentation, refill management, and annual re-enrollment.
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Omvoh Injection:
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Omvoh Injection assistance.
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Omvoh Injection (mirikizumab) is the subcutaneous maintenance phase of an IL-23 inhibitor biologic used to treat moderately-to-severely active ulcerative colitis and moderately-to-severely active Crohn’s disease in adults. After the IV induction phase with Omvoh Infusion (Weeks 0, 4, and 8), patients transition to the SC injection for long-term maintenance therapy given every four weeks.
How Omvoh Injection Works:
Omvoh is a monoclonal antibody that targets the IL-23 cytokine, a key driver of chronic inflammation in ulcerative colitis and Crohn’s disease. By selectively binding to the p19 subunit of IL-23, it prevents the cytokine from interacting with its receptor and dampens the immune response that damages the bowel. This consistent blockade helps reduce symptoms like abdominal pain and bloody stools while sustaining long-term remission.
Form and use:
Following an initial IV induction phase, Omvoh is transitioned to a maintenance dose of 200 mg administered every four weeks via subcutaneous injection. It is available in a prefilled pen or syringe and can be self-administered at home after receiving proper training from a specialty nurse. This maintenance schedule is designed to provide consistent medication levels starting at Week 12 of treatment.
Generic availability:
As of 2026, no biosimilar versions of Omvoh are available in the United States. Patients may consider other approved biologics for inflammatory bowel disease, including other IL-23 inhibitors like Skyrizi or TNF inhibitors that do have biosimilar options. The availability of various classes, such as JAK inhibitors and S1P modulators, provides multiple clinical pathways depending on a patient’s specific needs.
Warnings:
The use of Omvoh requires standard tuberculosis screening due to the risk of serious infections and the potential reactivation of latent TB. Other significant warnings include the risk of liver injury (hepatotoxicity) and hypersensitivity reactions to the medication. Patients are advised to avoid live vaccines during treatment and should monitor for symptoms such as jaundice, persistent fatigue, or new fevers.
The average retail price runs approximately $4,000–$5,000 per month for ongoing maintenance. Annual costs commonly reach $50,000–$60,000. Through AffordMyPrescriptions, qualifying patients receive Omvoh Injection at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
Omvoh Injection is given as a subcutaneous injection using a prefilled pen or syringe. The maintenance dose is 200 mg every four weeks, starting at Week 12 (after completing the IV induction phase). The injection can be self-administered at home after training by a specialty nurse.
Omvoh Infusion is the IV induction phase (3 doses at Weeks 0, 4, 8) used to rapidly induce remission. Omvoh Injection is the SC maintenance phase (200 mg every 4 weeks starting at Week 12) used to sustain that remission long-term. Both contain the same medicine (mirikizumab) but are administered differently to optimize induction and maintenance dosing.
Yes. Other options include risankizumab (Skyrizi, also IL-23), TNF inhibitors with biosimilars (adalimumab/Humira, infliximab/Remicade), integrin inhibitors (vedolizumab), IL-12/23 inhibitors (ustekinumab/Stelara, with biosimilars), JAK inhibitors (upadacitinib, tofacitinib), and S1P modulators (ozanimod). Whether one is a better clinical fit depends on prior treatments and tolerability.
Yes. Medicare Part D beneficiaries can typically qualify for Omvoh Patient Assistance, especially if you face specialty-tier copays you cannot afford. The manufacturer’s commercial copay savings program is reserved for commercially insured patients only — but the underlying PAP supports Medicare patients who meet income criteria.
If your initial application is denied, we explore alternative savings paths on your behalf — including independent foundations such as the PAN Foundation, HealthWell Foundation, or the Crohn’s & Colitis Foundation, the manufacturer’s copay assistance program if you have commercial insurance, or asking your gastroenterologist whether a different IBD biologic would be appropriate. If we cannot find a path, you will not be charged our service fee.
If you are struggling with the high cost of Omvoh Injection maintenance therapy, our team may be able to help you access assistance programs designed to make brand specialty IBD biologics affordable. Check your eligibility today.
Start free by filling out a simple online form.
Our specialist will contact you for a quick welcome call.
Our team handles everything, so you can focus on your health.